共 75 条
[1]
Reck M(2014)Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 25 iii27-iii39
[2]
Popat S(2002)Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 92-98
[3]
Reinmuth N(2001)Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 3210-3218
[4]
Schiller JH(2005)Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730) J Clin Oncol 23 190-196
[5]
Schiller JH(2006)Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[6]
Harrington D(2008)Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer J Clin Oncol 26 468-473
[7]
Kelly K(2006)Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials Intern Med J 36 216-220
[8]
Crowley J(1999)Underrepresentation of patients 65 years of age or older in cancer-treatment trials N Engl J Med 341 2061-2067
[9]
Bunn PA(2005)Non-small-cell lung cancer in a French department, (1982–1997): management and outcome Br J Cancer 92 459-466
[10]
Lilenbaum RC(2011)Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial Lancet 378 1079-1088